Innovating Works

ICD-Cancer

Financiado
Immunogenic cell death (ICD) in the cancer-immune dialogue
The success of most if not all anticancer treatments depends on the (re)activation of immunosurveillance, as this has been documented for several therapeutic modalities, not only immunotherapy, but also chemotherapy, targeted ther... The success of most if not all anticancer treatments depends on the (re)activation of immunosurveillance, as this has been documented for several therapeutic modalities, not only immunotherapy, but also chemotherapy, targeted therapy and radiotherapy. In response to antineoplastic drugs, malignant cells can undergo immunogenic cell death (ICD), thus exposing and releasing danger signals that act on pattern recognition receptors expressed by immune cells, in particular dendritic cells (DCs), to trigger the first steps of a therapeutically relevant anticancer immune response. Based on solid preliminary data and novel methodological approaches, we propose to obtain fundamental insights into the physicochemical properties and molecular mode of action of pharmacological ICD inducers (Objective 1), to create chemical-genetic systems for synthetic ICD induction for the study of ICD effects on the immune system without perturbation by pleiotropic anticancer drugs (Objective 2) and to identify new ICD-relevant immune checkpoints acting at the level of DCs (Objective 3). We will use this knowledge to generate an integrated view of the cancer-immune dialogue ignited, on one side, by malignant cells succumbing to ICD and, on the other side, DCs perceiving ICD, hence developing optimal strategies for the stimulation of tumor immunosurveillance (Objective 4). The concept of ICD has already been useful for patient-relevant biomarker discovery, drug development and trial design, strongly suggesting that a deeper exploration of this phenomenon will yield clinically relevant information. ver más
31/12/2027
3M€
Duración del proyecto: 60 meses Fecha Inicio: 2022-12-03
Fecha Fin: 2027-12-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-12-03
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2021-ADG: ERC ADVANCED GRANTS
Cerrada hace 3 años
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
UNIVERSITE PARIS CITE No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5